TY - JOUR
AU - Treisman, Daniel M
AU - Li, Yinghua
AU - Pierce, Brianna R
AU - Li, Chaoyang
AU - Chervenak, Andrew P
AU - Tomasek, Gerald J
AU - Lozano, Guillermina
AU - Zheng, Xiaoyan
AU - Kool, Marcel
AU - Zhu, Yuan
TI - Sox2+ cells in Sonic Hedgehog-subtype medulloblastoma resist p53-mediated cell-cycle arrest response and drive therapy-induced recurrence.
JO - Neuro-oncology advances
VL - 1
IS - 1
SN - 2632-2498
CY - Oxford
PB - Oxford University Press
M1 - DKFZ-2019-02713
SP - vdz027
PY - 2019
N1 - Neuro-Oncology Advances () = 2632-2498 (import from CrossRef, PubMed, )E-ISSN(s): 2632-2498
AB - High-intensity therapy effectively treats most TP53 wild-type (TP53-WT) Sonic Hedgehog-subgroup medulloblastomas (SHH-MBs), but often cause long-term deleterious neurotoxicities in children. Recent clinical trials investigating reduction/de-escalation of therapy for TP53-WT SHH-MBs caused poor overall survival. Here, we investigated whether reduced levels of p53-pathway activation by low-intensity therapy potentially contribute to diminished therapeutic efficacy.Using mouse SHH-MB models with different p53 activities, we investigated therapeutic efficacy by activating p53-mediated cell-cycle arrest versus p53-mediated apoptosis on radiation-induced recurrence.Upon radiation treatment, p53WT-mediated apoptosis was sufficient to eliminate all SHH-MB cells, including Sox2+ cells. The same treatment eliminated most Sox2- bulk tumor cells in SHH-MBs harboring p53R172P, an apoptosis-defective allele with cell-cycle arrest activity, via inducing robust neuronal differentiation. Rare quiescent Sox2+ cells survived radiation-enhanced p53R172P activation and entered a proliferative state, regenerating tumors. Transcriptomes of Sox2+ cells resembled quiescent Nestin-expressing progenitors in the developing cerebellum, expressing Olig2 known to suppress p53 and p21 expression. Importantly, high SOX2 expression is associated with poor survival of all four SHH-MB subgroups, independent of TP53 mutational status.Quiescent Sox2+ cells are efficiently eliminated by p53-mediated apoptosis, but not cell-cycle arrest and differentiation. Their survival contributes to tumor recurrence due to insufficient p53-pathway activation.
LB - PUB:(DE-HGF)16
C6 - pmid:31763624
C2 - pmc:PMC6860004
DO - DOI:10.1093/noajnl/vdz027
UR - https://inrepo02.dkfz.de/record/147736
ER -